We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Bayer Limited

The Atrium, Blackthorn Road, Dublin 18,
Telephone: +353 1 2999 313
Fax: +353 1 2061 456
Summary of Product Characteristics last updated on medicines.ie: 16/03/2017
SPC Jaydess 13.5 mg intrauterine delivery system

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 16/03/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   24-Feb-2017
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Added            Deleted

3. PHARMACEUTICAL FORM

[…]

The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. Removal Brown coloured removal threads are attached to the loop.

4.2 Posology and method of administration

[…]

Physical examination alone may not be sufficient to exclude partial perforation, which may have occurred even if the threads are still visible.

Jaydess can be distinguished from other IUSs by the combination of the visibility of the silver ring on ultrasound and the brown colour of the removal threads.

[…]

Patients with hepatic impairment

Jaydess has not been studied in women with hepatic impairment. Jaydess is contraindicated in women with acute liver disease or liver tumor tumour (see section 4.3).

4.4. Special warnings and precautions for use

[…]

·         marked increase of in blood pressure

[…]

Pelvic infection

While Jaydess and the inserter as such are sterile they may, due to bacterial contamination during insertion, become a vehicle for microbial transport in the upper genital tract.

[…]

Perforation

[…]

 

Breastfeeding
at time of insertion

Not breastfeeding
at time of insertion

Insertion ≤ 36 weeks after delivery

5.6

(
95% CI: 3.9-7.9,
n=6047 insertions)

1.7

(
95% CI: 0.8-3.1,
n=5927 insertions)

 

4.8 Undesirable effects

[…]

Reproductive system and breast disorders

Bleeding changes including increased and decreased menstrual bleeding, spotting, infrequent bleeeding bleeding and amenorrhoea

Ovarian cyst*

Vulvovaginitis

Upper genital tract infection

Dysmenorrhea

Breast pain/discomfort

Device expulsion (complete and partial)

Genital discharge

 

Uterine perforation**

 

5.1 Pharmacodynamic properties

[…]

Pharmacodynamic effects

[…]

Evidence of ovulation was seen in 34 out of 35 women in the first year, in 26 out of 27 women in the second year, and in all 27 26 women in the third year.

5.2 Pharmacokinetic properties

[…]

Distribution

Within one The concentration of SHBG declined on average by about 15% during the first month after insertion of Jaydess, the concentration of SHBG declines by about 30%. Thereafter, plateau-like SBHG concentrations are observed with a tendency to increase towards baseline values and remained stable over time the 3 year period of use.

[…]

Linearity/ non-linearity

[…]

During the first month of use of Jaydess, a mean SBHG A decrease of about 30% is observed which SHBG concentration leads to a decrease of total levonorgestrel concentration in serum indicating non-linear pharmacokinetics of levonorgestrel with regard to time.

[…]

Paediatric population

In a one-year phase III study in post-menarcheal female adolescents (mean age 16.2, range 12 to 18 years) pharmacokinetic analysis of 283 subjects adolescents showed estimated LNG serum concentrations slightly higher (approximately 10%) in adolescents compared to adults.

[…]

No differences in the pharmacokinetics of LNG are expected between adolescents and adults following insertion of Jaydess.

Ethnic differences

A three-year phase III study in the Asian-Pacific region (93% Asian women, 7% other ethnicities) using Jaydess has been performed. A comparison of pharmacokinetic characteristics of LNG of the Asian population in this study with that of the Caucasian population from another phase III study showed no clinically relevant difference in systemic exposure and other pharmacokinetic parameters. In addition, the daily release rate of Jaydess was the same in both populations.

No differences in the pharmacokinetics of LNG are expected between Caucasian and Asian women following insertion of Jaydess.

10. DATE OF REVISION OF THE TEXT

July 2016 February 2017

Updated on 22/08/2016 and displayed until 16/03/2017
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   31-Jul-2016
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Additional Bleeding Pattern inserted into Table 2 in Section 4.8- Undesirable Effects.

 Jaydess  - Irregular bleeding*
First 90 days -  39%
Second 90 days -  25%
End of year 1  - 18%
End of year 3 -  15%





Updated on 09/06/2015 and displayed until 22/08/2016
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   31-May-2015
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Jaydess – PA 1410/68/1
14101
BEC 7153 + 6960
www.medicines.ie

(Inserted Text; Deleted Text)

 

4.2          Posology and method of administration

Paediatric population

Safety and efficacy has not been studied in women aged below 18. Use of this product before menarche is not indicated. For data on safety and efficacy in adolescents, see section 5.1.

 

4.8          Undesirable effects

Summary of the safety profile

Table 1 2: Bleeding patterns reported with Jaydess in clinical trials

Paediatric population

The safety profile of Jaydess observed in a study of 304 adolescents was consistent with that in the adult population.

 

5.1          Pharmacodynamic properties

Clinical efficacy and safety

The safety profile of Jaydess observed in a study of 304 adolescents was consistent with that in the adult population. Efficacy is expected to be the same for adolescents under the age of 18 as for users 18 years and older.

 

5.2          Pharmacokinetic properties

…. Estimated in vivo delivery rates for different time points are provided in Table 2 3.

Table 2 3: Estimated in vivo release rates based on observed ex vivo residual content data

Paediatric population

In a one-year phase III study in post-menarcheal female adolescents (mean age 16.2, range 12 to 18 years) pharmacokinetic analysis of 283 subjects showed estimated LNG serum concentrations slightly higher (10%) in adolescents compared to adults. This correlates to the generally lower body weight in adolescents. The ranges estimated for adolescents lie, however, completely within the ranges estimated for adults, showing high similarity.

 

 

10           Date of revision of the text

April 2015 [To be inserted upon approval] May 2015
Updated on 29/04/2015 and displayed until 09/06/2015
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   21-Apr-2015
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Jaydess 13.5 mg intrauterine delivery system (PA 1410/68/1);

BP14043

Changes for www.medicines.ie

 

(Inserted text; Deleted text)

 

4.2 Posology and method of administration

Insertion and removal/ replacement

In case of a difficult insertion and/ or exceptional pain or bleeding during or after insertion, appropriate steps should be taken immediately to exclude perforation, such as physical examination and ultrasound.
Physical examination may not be sufficient to exclude partial perforation.

 

4.4 Special Warning and Precautions for Use

Medical examination/ consultation

Before insertion, a woman must be informed of the benefits and risks of Jaydess, including the signs and symptoms of perforation and the risk of ectopic pregnancy, see below.

 

Perforation

Perforation or penetration of the uterine corpus or cervix by an intrauterine contraceptive may occur rarely, most often during insertion, although it may not be detected until sometime later, and may decrease the effectiveness of Jaydess. In case of a difficult insertion and/ or exceptional pain or bleeding during or after insertion, appropriate steps should be taken immediately to exclude perforation, such as physical examination and ultrasound. Such a system must be removed; surgery may be required. The risk of perforations is increased in breast feeding women and may be increased in post partum insertions (see section 4.2) and in women with a fixed retroverted uterus.

In a large prospective comparative non-interventional cohort study in users of other IUDs (N=61,448 women), the incidence of perforation was 1.3 (95% CI: 1.1 - 1.6) per 1000 insertions in the entire study cohort; 1.4 (95% CI: 1.1 - 1.8) per 1000 insertions in the cohort of another LNG- IUS and 1.1 (95% CI: 0.7 - 1.6) per 1000 insertions in the copper IUD cohort.

The study showed that both breastfeeding at the time of insertion and insertion up to 36 weeks after giving birth were associated with an increased risk of perforation (see Table 1). These risk factors were independent of the type of IUD inserted.

Table 1: Incidence of perforation per 1000 insertions for the entire study cohort, stratified by breastfeeding and time since delivery at insertion (parous women)

 

Breastfeeding
at time of insertion

Not breastfeeding
at time of insertion

Insertion ≤ 36 weeks after delivery

5.6

95% CI: 3.9-7.9,
n=6047 insertions)

 

1.7

95% CI: 0.8-3.1,
n=5927 insertions)

 

Insertion > 36 weeks after delivery

1.6

(95% CI: 0.0-9.1,
n=608 insertions)

0.7

(95% CI: 0.5-1.1,
n=41,910 insertions)

 

The risk of perforations may be increased in women with fixed retroverted uterus.

 

Re-examination after insertion should follow the guidance given under the heading "Medical examination/consultation" which may be adapted as clinically indicated in women with risk factors for perforation.

 

Lost threads

If the removal threads are not visible at the cervix on follow-up examinations, unnoticed expulsion and pregnancy must be excluded. The threads may have been drawn up into the uterus or cervical canal and may reappear during the next menstrual period. If pregnancy has been excluded, the threads may usually be located by gently probing the cervical canal with a suitable instrument. If they cannot be found, the possibility of expulsion or perforation should be considered the system may have been expelled. Ultrasound exam may be used to ascertain the position of the system. If ultrasound is not available or is not successful, X-ray may be used to locate Jaydess.

 

4.8 Undesirable effects

Summary of the safety profile

The majority of women experience changes in menstrual bleeding pattern after insertion of Jaydess. Over time, the frequency of amenorrhoea and infrequent bleeding increases, and the frequency of both prolonged and frequent bleeding decreases. The following bleeding patterns were observed in clinical trials:

 

 

Table 1 2: Bleeding patterns reported with Jaydess in clinical trials…..

 

….

System Organ Class

Very Common

Common

Uncommon

Rare

Psychiatric disorders

 

Depressed mood/ Depression

 

 

Nervous system disorders

Headache

Migraine

 

 

Gastrointestinal disorders

Abdominal/pelvic pain

Nausea

 

 

 

Skin and subcutaneous tissue disorders

Acne/ Seborrhoea

 

Alopecia

 

Hirsutism

 

 

 

 

 

Reproductive system and breast disorders

Bleeding changes including increased and decreased menstrual bleeding, spotting, infrequent bleeding and amenorrhoea

Ovarian cyst*

Vulvovaginitis

 

Upper genital tract infection

Dysmenorrhea

Breast pain/discomfort

Device expulsion (complete and partial)

Genital discharge

 

Uterine perforation**

* In clinical trials ovarian cysts had to be reported as AEs if they were abnormal, non-functional cysts and/or had a diameter > 3 cm on ultrasound examination.
** This frequency is based on clinical trials that excluded breastfeeding women. In a large prospective comparative non-interventional cohort study with women using another LNG-IUS and copper IUDs, the frequency of perforation in women who were breastfeeding or had an insertion up to 36 weeks after delivery was “uncommon” (see section 4.4 under Perforation).

 

Description of selected adverse events

With the use of another LNG-IUS, cases of hypersensitivity including rash, urticaria and angioedema have been reported.

 

If a woman becomes pregnant while using Jaydess, the relative likelihood of this pregnancy being ectopic is increased (see section 4.4 under Ectopic Pregnancy).

The removal threads may be felt by the partner during intercourse.

Clinical trials with Jaydess excluded breast feeding women. A large post authorization safety study with other IUDs/IUSs shows an increased risk of perforation in breast feeding women (see section 4.4. under Perforation).

 

5.2 Pharmocokinetic properties

Levonorgestrel is released locally into the uterine cavity. The in vivo release curve is characterized by an initial steep decline that slows down progressively resulting in little change after 1 year until the end of the intended 3-year period of use. Estimated in vivo delivery rates for different time points are provided in Table 23.

Table 23: Estimated in vivo release rates based on observed ex vivo residual content data

 

10. Date of Revision of the Text

April 2014 April 2015

Updated on 15/04/2014 and displayed until 29/04/2015
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   03-Apr-2014
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



6.3 Shelf life

32

 

 

years.
In Section 6.3, the shelf-life has been changed from 2 to 3 years.

Date of revision has been changed from February 2014 to April 2014

 

10. DATE OF REVISION OF THE TEXT

February 2014 April 2014

Updated on 01/04/2014 and displayed until 15/04/2014
Reasons for adding or updating:
  • Addition of black triangle
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   27-Feb-2014
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



SUMMARY OF PRODUCT CHARACTERISTICS

 

   (Please insert "Inverted Black Triangle" symbol here.This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

 

4.8         Undesirable effects

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via IMB Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971;  Fax: +353 1 6762517. Website: www.imb.ie; e-mail: imbpharmacovigilance@imb.ie.

the national reporting system listed in Appendix V.

 

10.     DATE OF REVISION OF THE TEXT

 

February 2014

Updated on 02/01/2014 and displayed until 01/04/2014
Reasons for adding or updating:
  • New SPC for new product
Date of revision of text on the SPC:  
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

None provided

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Levonorgestrel